Overall survival with cetuximab every-2-weeks versus standard once-weekly administration schedule for first-line treatment of RAS wild-type metastatic colorectal cancer in patients with left- and right-sided primary tumour location

Eur J Cancer. 2023 Feb:180:85-88. doi: 10.1016/j.ejca.2022.11.021. Epub 2022 Nov 26.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents, Immunological* / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Cetuximab / therapeutic use
  • Colonic Neoplasms* / drug therapy
  • Colorectal Neoplasms* / drug therapy
  • Colorectal Neoplasms* / genetics
  • Humans
  • Proto-Oncogene Proteins p21(ras)
  • Rectal Neoplasms* / drug therapy

Substances

  • Cetuximab
  • Antineoplastic Agents, Immunological
  • Proto-Oncogene Proteins p21(ras)